/i.s3.glbimg.com/v1/AUTH_da025474c0c44edd99332dddb09cabe8/internal_photos/bs/2023/1/X/nkkB7tSdirnIUbGhakCQ/favicon-o-globo.png){kind=small}
/i.s3.glbimg.com/v1/AUTH_63b422c2caee4269b8b34177e8876b93/internal_photos/bs/2018/e/e/PAMa3oQXOPBUOsGgFyFw/valor-tenant-icon.png){kind=icon}
Overview
- McDonald's leaders said they are testing menu items for GLP-1 users, noting stronger interest in high‑protein choices and declines in snacking and sugary drinks.
- Independent and chain restaurants report shifts to smaller portions, higher‑protein dishes and zero‑alcohol pairings, with São Paulo’s NOU attributing about 15% of revenue to reduced‑size plates.
- Brazil’s pharmacy retail sold about 8.9 million GLP‑1 units in 2025, generating R$9.6 billion and an estimated 790,000 adults on continuous monthly use, according to Farma Brasil using IQVIA data.
- Novo Nordisk points to spillover effects reaching lifestyle categories, while industry voices say broader access will still be constrained by prescriptions and cost despite an expected 2026 liraglutide patent expiry.
- Nutrition researchers caution that evidence for specialized “GLP‑1 support” supplements is weak, advising balanced diets or standard vitamins when needed and noting deficiency estimates vary widely and are largely observational.